Lumican affects tumor cell functions, tumor-ECM interactions, angiogenesis and inflammatory response

Matrix Biology

Volumn 35, Issue , 2014, Pages 206-214

  Nikitovic, Dragana ^a   Papoutsidakis, Antonis ^a   Karamanos, Nikos K ^b   Tzanakakis, George N ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Extracellular matrix; Lumican; Signaling; Tumor stroma; Tumorigenesis

Indexed keywords

COLLAGEN; COLLAGENASE 3; CYCLIN D1; ELASTIN; GELATINASE A; GELATINASE B; GELSOLIN; INTERSTITIAL COLLAGENASE; KERATAN SULFATE; LUMICAN; MATRIX METALLOPROTEINASE; MESSENGER RNA; SCAFFOLD PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VERY LATE ACTIVATION ANTIGEN 2; PROTEOCHONDROITIN SULFATE;

ACTINIC KERATOSIS; ACUTE PANCREATITIS; APOPTOSIS; ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL FUNCTION; CELL SURVIVAL; COLONY FORMATION; COLORECTAL CANCER; EXTRACELLULAR MATRIX; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; LYMPH NODE METASTASIS; MELANOMA; METASTATIC MELANOMA; NEOVASCULARIZATION (PATHOLOGY); NON MELANOMA SKIN CANCER; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOMICS; SEBORRHEIC KERATOSIS; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CARCINOGENESIS; CHONDROITIN SULFATE PROTEOGLYCANS; EXTRACELLULAR MATRIX; HUMANS; INFLAMMATION; KERATAN SULFATE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84901457477     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2013.09.003     Document Type: Article

References (103)

1. Albig A.R., Roy T., Becenti D.J., Schiemann W.P. Transcriptome analysis of endothelial cell gene expression induced by growth on matrigel matrices: identification and characterization of MAGP-2 and lumican as novel regulators of angiogenesis. Angiogenesis 2007, 10:197-216.
2. Alowami S., Troup S., Al-Haddad S., Kirkpatrick I., Watson P.H. Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res. 2003, 5(R129-1):35.
3. Ameye L., Young M.F. Mice deficient in small leucine-rich proteoglycans: novel in vivo models for osteoporosis, o., Ehlers-Danlos syndrome, muscular dystrophy, and corneal diseases. Glycobiology 2002, 12:107R-116R.
4. Benayahu D., Shur I., Meller I., Issakow J. Cellular and molecular properties associated with osteosarcoma cells. J. Cell. Biochem. 1998, 84:108-114.
5. Beyrau M., Bodkin J.V., Nourshargh S. Neutrophil heterogeneity in health and disease: a revitalized avenue in inflammation and immunity. Open Biol. 2012, 2:120134.
6. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
7. Blochberger T.C., Cornuet P.K., Hassell J.R. Isolation and partial characterization of lumican and decorin from adult chicken corneas. A keratan sulfate-containing isoform of decorin is developmentally regulated. J. Biol. Chem. 1992, 267:20613-20619.
8. Blochberger T.C., Vergnes J.P., Hempel J., Hassell J.R. cDNA to chick lumican (corneal keratan sulfate proteoglycan) reveals homology to the small interstitial proteoglycan gene family and expression in muscle and intestine. J. Biol. Chem. 1992, 267:347-352.
9. Botella L.M., Sanz-Rodriguez F., Sanchez-Elsner T., Langa C., Ramirez J.R., Vary C., Roughley P.J., Bernabeu C. Lumican is down-regulated in cells expressing endoglin. Evidence for an inverse correlationship between Endoglin and Lumican expression. Matrix Biol. 2004, 22:561-572.
10. Brézillon S., Venteo L., Ramont L., D'Onofrio M.F., Perreau C., Pluot M., Maquart F.X., Wegrowski Y. Expression of lumican, a small leucine-rich proteoglycan with antitumour activity, in human malignant melanoma. Clin. Exp. Dermatol. 2007, 32:405-416.
11. Brezillon S., Zeltz C., Schneider L., Terryn C., Vuillermoz B., Ramont L., Perrau C., Pluot M., Diebold M.D., Radwanska A., Malicka-Blaszkiewicz M., Maquart F.X., Wegrowski Y. Lumican inhibits B16F1 melanoma cell lung metastasis. J. Physiol. Pharmacol. Suppl. 2009, 4:15-22.
12. Brézillon S., Pietraszek K., Maquart F.X., Wegrowski Y. Lumican effects in the control of tumour progression and their links with metalloproteinases and integrins. FEBS J. 2013, 280:2369-2381.
13. Coulson-Thomas V.J., Gesteira T.F., Coulson-Thomas Y.M., Vicente C.M., Tersariol I.L., Nader H.B., Toma L. Fibroblast and prostate tumor cell cross-talk: fibroblast differentiation, TGF-β, and extracellular matrix down-regulation. Exp Cell Res. 2010, 316:3207-3226.
14. Coulson-Thomas V.J., Coulson-Thomas Y.M., Gesteira T.F., Andrade de Paula C.A., Carneiro C.R., Ortiz V., Toma L., Kao W.W., Nader H.B. Lumican expression, localization and antitumor activity in prostate cancer. Exp Cell Res. 2013, 319:967-981.
15. Czekanska E.M., Stoddart M.J., Richards R.G., Hayes J.S. In search of an osteoblast cell model for in vitro research. Eur. Cell Mater. 2012, 24:1-17.
16. Danielson K.G., Fazzio A., Cohen I., Cannizzaro L.A., Eichstetter I., Iozzo R.V. The human decorin gene: intron-exon organization, discovery of two alternatively spliced exons in the 5' untranslated region, and mapping of the gene to chromosome 12q23. Genomics 1993, 5:46-60.
17. De Larco J.E., Wuertz B.R., Furcht L.T. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin. Cancer Res. 2004, 10(15):4895-4900.
18. de Wit M., Belt E.J., Delis-van Diemen P.M., Carvalho B., Coupé V.M., Stockmann H.B., Bril H., Beliën J.A., Fijneman R.J., Meijer G.A. Lumican and versican are associated with good outcome in stage II and III colon cancer. Ann. Surg. Oncol. 2012, (Epub ahead of print).
19. D'Onofrio M.F., Brezillon S., Baranek T., Perreau C., Roughley P.J., Maquart F.X., Wegrowski Y. Identification of beta1 integrin as mediator of melanoma cell adhesion to lumican. Biochem. Biophys. Res. Commun. 2008, 365:266-272.
20. Eshchenko T.Y., Rykova V., Chernakov A.E., Sidorov S.V., Grigorieva E.V. Expression of different proteoglycans in human breast tumors. Biochemistry (Mosc) 2007, 72:1016-1020.
21. Finn O.J. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann. Oncol. 2012, 8:viii6-viii9.
22. Funderburgh J.L., Mitschler R.R., Funderburgh M.L., Roth M.R., Chapes S.K., Conrad G.W. Macrophage receptors for lumican. A corneal keratan sulfate proteoglycan. Invest. Ophthalmol. Vis. Sci. 1997, 38:1159-1167.
23. Geng Y., McQuillan D., Roughley P.J. SLRP interaction can protect collagen fibrils from cleavage by collagenases. Matrix Biol. 2006, 25:484-491.
24. Hagedorn M., Javerzat S., Gilges D., Meyre A., de Lafarge B., Eichmann A., Bikfalvi A. Accessing key steps of human tumor progression in vivo by using an avian embryo model. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:1643-1648.
25. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
26. Hayashi Y., Call M.K., Chikama T., Liu H., Carlson E.C., Sun Y., Pearlman E., Funderburgh J.L., Babcock G., Liu C.Y., Ohashi Y., Kao W.W. Lumican is required for neutrophil extravasation following corneal injury and wound healing. J. Cell Sci. 2010, 123:2895-2987.
27. Hedbom E., Heinegård D. Binding of fibromodulin and decorin to separate sites on fibrillar collagens. J. Biol. Chem. 1993, 268:27307-27312.
28. Herpin A., Cunningham C. Cross-talk between the bone morphogenetic protein pathway and other major signaling pathways results in tightly regulated cell-specific outcomes. FEBS J. 2008, 274:2977-2985.
29. Hildebrand A., Romarís M., Rasmussen L.M., Heinegård D., Twardzik D.R., Border W.A., Ruoslahti E. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem. J. 1994, 302(Pt 2):527-534.
30. Holland J.W., Meehan K.L., Redmond S.L., Dawkins H.J. Purification of the keratan sulfate proteoglycan expressed in prostatic secretory cells and its identification as lumican. Prostate 2004, 59:252-259.
31. Iozzo R.V. The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit. Rev. Biochem. Mol. Biol. 1997, 32:141-174.
32. Iozzo R.V., Murdoch A.D. Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity. FASEB J. 1996, 10:598-614.
33. Ishiwata T., Cho K., Kawahara K., Yamamoto T., Fujiwara Y., Uchida E., Tajiri T., Naito Z. Role of lumican in cancer cells and adjacent stromal tissues in human pancreatic cancer. Oncol. Rep. 2007, 18:537-543.
34. Jodele S., Blavier L., Yoon J.M., DeClerck Y.A. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev. 2006, 25:35-43.
35. Jukkola A., Risteli L., Melkko J., Risteli J. Procollagen synthesis and extracellular matrix deposition in MG-63 osteosarcoma cells. J. Bone Miner. Res. 1993, 8:651-657.
36. Kalamajski S., Oldberg A. Homologous sequence in lumican and fibromodulin leucine-rich repeat 5-7 competes for collagen binding. J. Biol. Chem. 2009, 284:534-539.
37. Kalamajski S., Oldberg A. The role of small leucine-rich proteoglycans in collagen fibrillogenesis. Matrix Biol. 2010, 29:248-253.
38. Kelemen L.E., Couch F.J., Ahmed S., Dunning A.M., Pharoah P.D., Easton D.F., Fredericksen Z.S., Vierkant R.A., Pankratz V.S., Goode E.L., Scott C.G., Rider D.N., Wang X., Cerhan J.R., Vachon C.M. Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studies. Breast Cancer Res. 2008, 10:R98.
39. Kolacna L., Bakesová J., Varga F., Kostakova E., Planka L., Necas A., Lukas D., Amler E., Pelouch V. Biochemical and biophysical aspects of collagen nanostructure in the extracellular matrix. Physiol. Res. 2007, 56:S51-S60.
40. Köninger J., Giese T., di Mola F.F., Wente M.N., Esposito I., Bachem M.G., Giese N.A., Büchler M.W., Friess H. Pancreatic tumor cells influence the composition of the extracellular matrix. Biochem. Biophys. Res. Commun. 2004, 322:943-949.
41. Lee S.B.K., Hamad A.R., Chakravarti S. Extracellular matrix lumican deposited on the surface of neutrophils promotes migration by binding to beta2 integrin. J. Biol. Chem. 2009, 284:23662-23669.
42. Lee S., Bowrin K., Hamad A.R., Chakravarti S. Extracellular matrix lumican deposited on the surface of neutrophils promotes migration by binding to β2 integrin. J. Biol. Chem. 2009, 284:23662-23669.
43. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., Yamauchi M., Gasser D.L., Weaver V.M. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
44. Leygue E., Snell L., Dotzlaw H., Hole K., Hiller-Hitchcock T., Roughley P.J., Watson P.H., Murphy L.C. Expression of lumican in human breast carcinoma. Cancer Res. 1998, 58:1348-1352.
45. Leygue E., Snell L., Dotzlaw H., Troup S., Hiller-Hitchcock T., Murphy L.C., Roughley P.J., Watson P.H. Lumican and decorin are differentially expressed in human breast carcinoma. J. Pathol. 2000, 192:313-320.
46. Li Y., Aoki T., Mori Y., Ahmad M., Miyamori H., Takino T., Sato H. Cleavage of lumican by membrane-type matrix metalloproteinase-1 abrogates this proteoglycan-mediated suppression of tumor cell colony formation in soft agar. Cancer Res. 2004, 64:7058-7064.
47. Liu X.J., Kong F., Wang Y.H., Zheng J.H., Wan W.D., Deng C.L., Mao G.Y., Li J., Yang X.M., Zhang Y.L., Zhang X.L., Yang S.L., Zhang Z.G. Lumican accelerates wound healing by enhancing α2β1 integrin-mediated fibroblast contractility. PLoS One 2013, 8:e67124.
48. Lu Y.P., Ishiwata T., Kawahara K., Watanabe M., Naito Z., Moriyama Y., Sugisaki Y., Asano G. Expression of lumican in human colorectal cancer cells. Pathol. Int. 2002, 52:519-526.
49. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 2012, 196:395-406.
50. Malinowski M., Pietraszek K., Perreau C., Boguslawski M., Decot V., Stoltz J.F., Vallar L., Niewiarowska J., Cierniewski C., Maquart F.X., Wegrowski Y., Brézillon S. Effect of lumican on the migration of human mesenchymal stem cells and endothelial progenitor cells: involvement of matrix metalloproteinase-14. PLoS One 2012, 7:e50709.
51. Matsuda Y., Yamamoto T., Kudo M., Kawahara K., Kawamoto M., Nakajima Y., Koizumi K., Nakazawa N., Ishiwata T., Naito Z. Expression and roles of lumican in lung adenocarcinoma and squamous cell carcinoma. Int. J. Oncol. 2008, 33:1177-1185.
52. McEwan P.A., Scott P.G., Bishop P.N., Bella J. Structural correlations in the family of small leucine-rich repeat proteins and proteoglycans. J. Struct. Biol. 2006, 155:294-305.
53. Melching L., Roughley P. Modulation of keratan sulfate synthesis on lumican by the action of cytokines on human articular chondrocytes. Matrix Biol. 1999, 18:381-390.
54. Missan D.S., DiPersio M. Integrin control of tumor invasion. Crit. Rev. Eukaryot. Gene Expr. 2012, 22:309-324.
55. Naito Z. Role of the small leucine-rich proteoglycan (SLRP) family in pathological lesions and cancer cell growth. J. Nippon Med. Sch. 2005, 72:137-145.
56. Naito Z., Ishiwata T., Kurban G., Teduka K., Kawamoto Y., Kawahara K., Sugisaki Y. Expression and accumulation of lumican protein in uterine cervical cancer cells at the periphery of cancer nests. Int. J. Oncol. 2002, 20:943-948.
57. Naito Z., Isahiwata T., Lu Y.P., Teduka K., Fujii T., Kawahara K., Sugisaki Y. Transient and ectopic expression of lumican by acinar cells in L-arginine-induced acute pancreatitis. Exp. Mol. Pathol. 2003, 74:33-39.
58. Niewiarowska J., Brézillon S., Sacewicz-Hofman I., Bednarek R., Maquart F.X., Malinowski M., Wiktorska M., Wegrowski Y., Cierniewski C.S. Lumican inhibits angiogenesis by interfering with α2β1 receptor activity and downregulating MMP-14 expression. Thromb. Res. 2011, 128:452-457.
59. Nikitovic D., Katonis P., Tsatsakis A., Karamanos N.K., Tzanakakis G.N. Lumican, a small leucine-rich proteoglycan. IUBMB Life 2008, 60:818-823. (a).
60. Nikitovic D., Berdiaki A., Zafiropoulos A., Katonis P., Tsatsakis A., Karamanos N.K., Tzanakakis G.N. Lumican expression is positively correlated with the differentiation and negatively with the growth of human osteosarcoma cells. FEBS J. 2008, 275:350-361. (a).
61. Nikitovic D., Berdiaki K., Chalkiadaki G., Karamanos N., Tzanakakis G. The role of SLRP-proteoglycans in osteosarcoma pathogenesis. Connect. Tissue Res. 2008, 49:235-238. (c).
62. Nikitovic D., Aggelidakis J., Young M.F., Iozzo R.V., Karamanos N.K., Tzanakakis G.N. The biology of small leucine-rich proteoglycans in bone pathophysiology. J. Biol. Chem. 2012, 287:33926-33933.
63. Nikitovic D., Banos A., Tsatsakis A., Karamanos N.K., Tzanakakis G.N. Could growth factor-mediated extracellular matrix deposition and degradation offer the ground for directed pharmacological targeting in fibrosarcoma?. Curr. Med. Chem. 2013, 20:2868-2880.
64. Okano T., Kondo T., Kakisaka T., Fujii K., Yamada M., Kato H., Nishimura T., Gemma A., Kudoh S., Hirohashi S. Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics 2006, 6:3938-3948.
65. Oldberg A., Kalamajski S., Salnikov A.V., Stuhr L., Mörgelin M., Reed R.K., Heldin N.E., Rubin K. Collagen-binding proteoglycan fibromodulin can determine stroma matrix structure and fluid balance in experimental carcinoma. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(35):13966-13971.
66. Owen-Schaub L., Chan H., Cusac,k J.C., Roth J., Hill L.L. Fas and Fas ligand interactions in malignant disease. Int. J. Oncol. 2000, 17:5-12.
67. Pan S., Chen R., Stevens T., Bronner M.P., May D., Tamura Y., McIntosh M.W., Brentnall T.A. Proteomics portrait of archival lesions of chronic pancreatitis. PLoS One 2011, 6:27574.
68. Panis C., Pizzati L., Herrera A.C., Cecchini R., Abdelhay E. Putative circulating markers of the early and advanced stages of breast cancer identified by high-resolution label-free proteomics. Cancer Lett. 2013, 330:57-66.
69. Ping Lu Y., Ishiwata T., Asano G. Lumican expression in alpha cells of islets in pancreas and pancreatic cancer cells. J. Pathol. 2002, 196:324-330.
70. Provenzano P.P., Eliceiri K., Campbell J.M., Inman D.R., White J.G., Keely P.J. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med. 2006, 4:38.
71. Radwanska A., Baczynska D., Nowak D., Brézillon S., Popow A., Maquart F.X., Wegrowski Y., Malicka-Blaszkiewicz M. Lumican affects actin cytoskeletal organization in human melanoma A375 cells. Life Sci. 2008, 83:651-660.
72. Radwanska A., Litwin M., Nowak D., Baczynska D., Wegrowski Y., Maquart F.X., Malicka-Blaszkiewicz M. Overexpression of lumican affects the migration of human colon cancer cells through up-regulation of gelsolin and filamentous actin reorganization. Exp Cell Res. 2012, 318:2312-2323.
73. Raouf A., Ganss B., McMahon C., Vary C., Roughley P.J., Seth A. Lumican is a major proteoglycan component of the bone matrix. Matrix Biol. 2002, 21:361-367.
74. Reed C.C., Iozzo R.V. The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj. J. 2002, 19:249-255.
75. Schaefer L., Iozzo R.V. Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J. Biol. Chem. 2008, 283:21305-23109.
76. Schaefer L., Schaefer R.M. Review Proteoglycans: from structural compound to signaling molecules. Cell Tissue Res. 2010, 339:237-246.
77. Seomun Y., Joo C.K. Lumican induces human corneal epithelial cell migration and integrin expression via ERK 1/2 signaling. Biochem. Biophys. Res. Commun. 2008, 372:221-225.
78. Seya T., Tanaka N., Shinji S., Yokoi K., Koizumi M., Teranishi N., Yamashita K., Tajiri T., Ishiwata T., Naito Z. Lumican expression in advanced colorectal cancer with nodal metastasis correlates with poor prognosis. Oncol. Rep. 2006, 16:1225-1230.
79. Sharma B., Ramus M.D., Kirkwood C.T., Sperry E.E., Chu P.H., Kao W.W., Albig A.R. Lumican Exhibits Anti-Angiogenic Activity in a Context Specific Manner. Cancer Microenviron. 2013, (E-pub).
80. Shinji S., Tajiri T., Ishiwata T., Seya T., Tanaka N., Naito Z. Different expression levels of lumican in human carcinoid tumor and neuroendocrine cell carcinoma. Int. J. Oncol. 2005, 26:873-880.
81. Sifaki M., Assouti M., Nikitovic D., Krasagakis K., Karamanos N.K., Tzanakakis G.N. Lumican, a small leucine-rich proteoglycan substituted with keratan sulfate chains is expressed and secreted by human melanoma cells and not normal melanocytes. IUBMB Life 2006, 58:606-610.
82. Somiari R.I., Sulivan A., Russell S., Somiari S., Hu H., Jordan R., George A., Katenhusen R., Buchowiecka A., Arciero C., Brzeski H., Hooke J., Shriver C. High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast. Proteomics 2003, 3:1863-1873.
83. Sorokin L. The impact of the extracellular matrix on inflammation. Nat. Rev. Immunol. 2010, 10:712-723.
84. Stamov D.R., Müller A., Wegrowski Y., Brezillon S., Franz C.M. Quantitative analysis of type I collagen fibril regulation by lumican and decorin using AFM. J. Struct. Biol. 2013, S1047-S8477. (pii: (13)00154-8).
85. Suhovskih A.V., Mostowich L.A., Kunin I.S., Boboev M.M., Nepomnyashchikh G.I., Aidagulova S.V., Grigorieva E.V. Proteoglycan expression in normal human prostate tissue and prostate cancer. ISRN Oncol. 2013, 18:680136.
86. Svensson L., Narlid I., Oldberg A. Fibromodulin and lumican bind to the same region on collagen type I fibrils. FEBS Lett. 2000, 470:178-182.
87. Taichman R.S., Reilly M.J., Emerson S.G. Human osteosarcomas inhibit hematopoietic colony formation: partial reversal by antibody to transforming growth factor-beta 1. Bone 1994, 21:353-361.
88. Takayama R., Ishiwata T., Ansai S.I., Yamamoto T., Matsuda Y., Naito Z., Kawana S. Lumican as a novel marker for differential diagnosis of bowen disease and actinic keratosis. Am. J. Dermatopathol. 2013, (E-pub (a)).
89. Takayama R., Ansai S.I., Ishiwata T., Yamamoto T., Matsuda Y., Naito Z., Kawana S. Expression of lumican in hidroacanthoma simplex and clonal-type seborrheic keratosis as a potent differential diagnostic marker. Am. J. Dermatopathol. 2013, (Epub (b)).
90. Troup S., Niue C., Kliewer E.V., Parisien M., Roskelley C., Chakravarti S., Roughley P.J., Murphy L.C., Watson P.H. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin. Cancer Res. 2003, 9:207-214.
91. Vij N., Roberts L., Joyce S., Chakravarti S. Lumican regulates corneal inflammatory responses by modulating Fas-Fas ligand signaling. Invest. Ophthalmol. Vis. Sci. 2005, 46:88-95.
92. Villa-Morales M., Fernández-Piqueras J. Targeting the Fas/FasL signaling pathway in cancer therapy. Expert. Opin. Ther. Targets 2012, 16(1):85-101.
93. Vuillermoz B., Khoruzhenko A., D'Onofrio M.F., Ramont L., Venteo L., Perreau C., Antonicelli F., Maquart F.X., Wegrowski Y. The small leucine-rich proteoglycan lumican inhibits melanoma progression. Exp. Cell Res. 2004, 296:294-306.
94. Watanabe T., Komuro Y., Kiyomatsu T., Kanazawa T., Kazama Y., Tanaka J., Tanaka T., Yamamoto Y., Shirane M., Muto T., Nagawa H. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res. 2006, 66:3370-3374.
95. Weber I.T., Harrison R.W., Iozzo R.V. Model structure of decorin and implications for collagen fibrillogenesis. J. Biol. Chem. 1996, 271:31767-31770.
96. Williams K.E., Fulford L.A., Albig A.R. Lumican reduces tumor growth via induction of fas-mediated endothelial cell apoptosis. Cancer Microenviron. 2010, 18:115-126.
97. Wu F., Chakrawarti S. Differential expression of inflammatory and fibrogenic genes and their regulation by NF-kappaB inhibition in a mouse model of chronic colitis. J. Immunol. 2007, 179:6988-7000.
98. Wu F., Vij N., Roberts L., Lopez-Briones S., Joyce S., Chakravarti S. A novel role of the lumican core protein in bacterial lipopolysaccharide-induced innate immune response. J. Biol. Chem. 2007, 282:26409-26417.
99. Yamamoto T., Matsusa Y., Kawahara K., Ishiwata T., Naito Z. Secreted 70kDa lumican stimulates growth and inhibits invasion of human pancreatic cancer. Cancer Lett. 2012, 320:31-39.
100. Yang Z.X., Lu C.Y., Yang Y.L., Dou K.F., Tao K.S. Lumican expression in pancreatic ductal adenocarcinoma. Hepatogastroenterology 2013, 122:349-353.
101. Zeltz C., Brézillon S., Perreau C., Ramont L., Maquart F.X., Wegrowski Y. Lumcorin: a leucine-rich repeat 9-derived peptide from human lumican inhibiting melanoma cell migration. FEBS Lett. 2009, 583:3027-3032.
102. Zeltz C., Brézillon S., Kapyla J., Eble J.A., Bobichon H., Terryn C., Perreau C., Franz C.M., Heino J., Maquart F.-X., Wegrowski Y. Lumican inhibits cell migration through α2β1 integrin. Exp. Cell Res. 2010, 316:2922-2931.
103. Zhang Y., Mao X., Schwend T., Littlechild S., Conrad G.W. Resistance of corneal RFUVA-cross-linked collagens and small leucine-rich proteoglycans to degradation by matrix metalloproteinases. Invest. Ophthalmol. Vis. Sci. 2013, 54:1014-1025.